



| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 50μL*10mM(DMSO) | ¥169 | 咨询 | |
| 100μL*10mM(DMSO) | ¥269 | 咨询 | |
| 250μL*10mM(DMSO) | ¥539 | 咨询 | |
| 500μL*10mM(DMSO) | ¥899 | 咨询 | |
| 10mM*1mL(DMSO) | ¥1307 | 咨询 | |
| 1mg | ¥595 | 咨询 | |
| 2mg | ¥760 | 咨询 | |
| 5mg | ¥1134 | 咨询 | |
| 10mg | ¥2016 | 咨询 | |
| 25mg | ¥3213 | 咨询 | |
| 50mg | ¥4505 | 咨询 | |
| 100mg | ¥6224 | 咨询 |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解


| 产品名称 | BTK ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-1746 |
+++
BTK, IC50: 1.9 nM | 98% | |||||||||||||||||
| Spebrutinib |
++++
BTK, IC50: <0.5 nM | 98+% | |||||||||||||||||
| Acalabrutinib |
++
BTK, IC50: 3nM | 98% | |||||||||||||||||
| CNX-774 |
+++
BTK, IC50: <1 nM | 99%+ | |||||||||||||||||
| Ibrutinib |
++++
BTK, IC50: 0.5 nM | 98% | |||||||||||||||||
| ONO-4059 analog |
+
BTK, IC50: 23.9 nM | 98% | |||||||||||||||||
| RN486 |
++
BTK, IC50: 4 nM | 99%+ | |||||||||||||||||
| (Z)-LFM-A13 |
+
BTK, Ki: 1.4 μM | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Bruton’s tyrosine kinase (BTK), an essential component of the B-cell antigen receptor (BCR) pathway, has emerged as novel target in the treatment of B-cell malignancies . Zanubrutinib is a selective BTK inhibitor. It demonstrates nanomolar BTK inhibition activity in both biochemical and cellular assays. In several MCL and DLBCL cell lines, Zanubrutinib inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation. Zanubrutinib induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the systemic model, the median survival of Zanubrutinib 25 mg/kg BID group is significantly longer than those of both PCI-32765 50 mg/kg QD and BID groups. In an ABC-subtype DLBCL (TMD-8) subcutaneous xenograft model, Zanubrutinib also demonstrates better anti-tumor activity than PCI-32765. Preliminary 14-day toxicity study in rats shows that Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250 mg/kg/day .[1] |
| 作用机制 | Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor. |
| 计算器 | ||||
| 存储液制备 | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 2.12mL 0.42mL 0.21mL | 10.60mL 2.12mL 1.06mL | 21.21mL 4.24mL 2.12mL | |
| CAS号 | 1691249-45-2 |
| 分子式 | C27H29N5O3 |
| 分子量 | 471.55 |
| SMILES Code | O=C(C1=C2NCC[C@@H](C3CCN(C(C=C)=O)CC3)N2N=C1C4=CC=C(OC5=CC=CC=C5)C=C4)N |
| MDL No. | MFCD31567461 |
| 别名 | 赞鲁替尼 ;BGB-3111 |
| 运输 | 蓝冰 |
| InChI Key | RNOAOAWBMHREKO-QFIPXVFZSA-N |
| Pubchem ID | 135565884 |
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 | DMSO: 190 mg/mL(402.93 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1